APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemorrhagic Septicemia Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hemorrhagic Septicemia Vaccines Market Outlook and Growth Opportunities 2026

22 December 2025202 pages

Choose your research edition.

Industry ResearchHemorrhagic Septicemia Vaccines Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemorrhagic Septicemia Vaccines Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Hemorrhagic Septicemia Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemorrhagic Septicemia Vaccines Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemorrhagic Septicemia Vaccines Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Hemorrhagic Septicemia Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hemorrhagic Septicemia Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hemorrhagic Septicemia Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hemorrhagic Septicemia Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hemorrhagic Septicemia Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hemorrhagic Septicemia Vaccines market include Zoetis, Vecol, National Veterinary Research Institute, Limor de Colombia, Laboratorios Ovejero, Laboratorios Laverlam, LABIOFAM, Intervac (PVT) Ltd and Institute of Veterinary Preventive Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hemorrhagic Septicemia Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hemorrhagic Septicemia Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hemorrhagic Septicemia Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hemorrhagic Septicemia Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Hemorrhagic Septicemia Vaccines Segment by Company

Zoetis

Vecol

National Veterinary Research Institute

Limor de Colombia

Laboratorios Ovejero

Laboratorios Laverlam

LABIOFAM

Intervac (PVT) Ltd

Institute of Veterinary Preventive Medicine

Institute of Animal Health and Veterinary Biologicals

Indian Immunologicals Limited

FATRO

Ceva Santé Animale

C.A. Laboratorios Asociados (CALA)

Brilliant Bio Pharma

Bio-Labs (PVT) Limited

Hemorrhagic Septicemia Vaccines Segment by Type

Oil–adjuvant Vaccines

Aluminum hydroxide-adjuvant Vaccines

Hemorrhagic Septicemia Vaccines Segment by Application

Cattle

Buffaloes

Hemorrhagic Septicemia Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hemorrhagic Septicemia Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hemorrhagic Septicemia Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hemorrhagic Septicemia Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Hemorrhagic Septicemia Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemorrhagic Septicemia Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemorrhagic Septicemia Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemorrhagic Septicemia Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hemorrhagic Septicemia Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hemorrhagic Septicemia Vaccines industry.

Chapter 3: Detailed analysis of Hemorrhagic Septicemia Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hemorrhagic Septicemia Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hemorrhagic Septicemia Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hemorrhagic Septicemia Vaccines Industry Trends Table 2. Hemorrhagic Septicemia Vaccines Industry Drivers Table 3. Hemorrhagic Septicemia Vaccines Industry Opportunities and Challenges Table 4. Hemorrhagic Septicemia Vaccines Industry Restraints Table 5. Global Hemorrhagic Septicemia Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hemorrhagic Septicemia Vaccines Revenue Share by Company (2021-2026) Table 7. Global Hemorrhagic Septicemia Vaccines Sales Volume by Company (m units) & (2021-2026) Table 8. Global Hemorrhagic Septicemia Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Hemorrhagic Septicemia Vaccines Average Price (US$/k unit) of Company (2021-2026) Table 10. Global Hemorrhagic Septicemia Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hemorrhagic Septicemia Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Hemorrhagic Septicemia Vaccines Company, Product Type & Application Table 13. Global Hemorrhagic Septicemia Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hemorrhagic Septicemia Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oil–adjuvant Vaccines Table 18. Significant Companies of Aluminum hydroxide-adjuvant Vaccines Table 19. Global Hemorrhagic Septicemia Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (m units) Table 20. Global Hemorrhagic Septicemia Vaccines Sales Volume by Type (2021-2026) & (m units) Table 21. Global Hemorrhagic Septicemia Vaccines Sales Volume by Type (2027-2032) & (m units) Table 22. Global Hemorrhagic Septicemia Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Hemorrhagic Septicemia Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Hemorrhagic Septicemia Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hemorrhagic Septicemia Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Hemorrhagic Septicemia Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Hemorrhagic Septicemia Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Hemorrhagic Septicemia Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Cattle Table 30. Significant Companies of Buffaloes Table 31. Global Hemorrhagic Septicemia Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (m units) Table 32. Global Hemorrhagic Septicemia Vaccines Sales Volume by Application (2021-2026) & (m units) Table 33. Global Hemorrhagic Septicemia Vaccines Sales Volume by Application (2027-2032) & (m units) Table 34. Global Hemorrhagic Septicemia Vaccines Sales Volume Share by Application (2021-2026) Table 35. Global Hemorrhagic Septicemia Vaccines Sales Volume Share by Application (2027-2032) Table 36. Global Hemorrhagic Septicemia Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Hemorrhagic Septicemia Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Hemorrhagic Septicemia Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Hemorrhagic Septicemia Vaccines Sales Value Share by Application (2021-2026) Table 40. Global Hemorrhagic Septicemia Vaccines Sales Value Share by Application (2027-2032) Table 41. Global Hemorrhagic Septicemia Vaccines Sales by Region: 2021 VS 2025 VS 2032 (m units) Table 42. Global Hemorrhagic Septicemia Vaccines Sales by Region (2021-2026) & (m units) Table 43. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Region (2021-2026) Table 44. Global Hemorrhagic Septicemia Vaccines Sales by Region (2027-2032) & (m units) Table 45. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Region (2027-2032) Table 46. Global Hemorrhagic Septicemia Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Hemorrhagic Septicemia Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Hemorrhagic Septicemia Vaccines Sales Value Share by Region (2021-2026) Table 49. Global Hemorrhagic Septicemia Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Hemorrhagic Septicemia Vaccines Sales Value Share by Region (2027-2032) Table 51. Global Hemorrhagic Septicemia Vaccines Market Average Price (US$/k unit) by Region (2021-2026) Table 52. Global Hemorrhagic Septicemia Vaccines Market Average Price (US$/k unit) by Region (2027-2032) Table 53. Global Hemorrhagic Septicemia Vaccines Sales by Country: 2021 VS 2025 VS 2032 (m units) Table 54. Global Hemorrhagic Septicemia Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Hemorrhagic Septicemia Vaccines Sales by Country (2021-2026) & (m units) Table 56. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Country (2021-2026) Table 57. Global Hemorrhagic Septicemia Vaccines Sales by Country (2027-2032) & (m units) Table 58. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Country (2027-2032) Table 59. Global Hemorrhagic Septicemia Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Hemorrhagic Septicemia Vaccines Sales Value Market Share by Country (2021-2026) Table 61. Global Hemorrhagic Septicemia Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Hemorrhagic Septicemia Vaccines Sales Value Market Share by Country (2027-2032) Table 63. Zoetis Company Information Table 64. Zoetis Business Overview Table 65. Zoetis Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 66. Zoetis Hemorrhagic Septicemia Vaccines Product Portfolio Table 67. Zoetis Recent Development Table 68. Vecol Company Information Table 69. Vecol Business Overview Table 70. Vecol Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 71. Vecol Hemorrhagic Septicemia Vaccines Product Portfolio Table 72. Vecol Recent Development Table 73. National Veterinary Research Institute Company Information Table 74. National Veterinary Research Institute Business Overview Table 75. National Veterinary Research Institute Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 76. National Veterinary Research Institute Hemorrhagic Septicemia Vaccines Product Portfolio Table 77. National Veterinary Research Institute Recent Development Table 78. Limor de Colombia Company Information Table 79. Limor de Colombia Business Overview Table 80. Limor de Colombia Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 81. Limor de Colombia Hemorrhagic Septicemia Vaccines Product Portfolio Table 82. Limor de Colombia Recent Development Table 83. Laboratorios Ovejero Company Information Table 84. Laboratorios Ovejero Business Overview Table 85. Laboratorios Ovejero Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 86. Laboratorios Ovejero Hemorrhagic Septicemia Vaccines Product Portfolio Table 87. Laboratorios Ovejero Recent Development Table 88. Laboratorios Laverlam Company Information Table 89. Laboratorios Laverlam Business Overview Table 90. Laboratorios Laverlam Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 91. Laboratorios Laverlam Hemorrhagic Septicemia Vaccines Product Portfolio Table 92. Laboratorios Laverlam Recent Development Table 93. LABIOFAM Company Information Table 94. LABIOFAM Business Overview Table 95. LABIOFAM Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 96. LABIOFAM Hemorrhagic Septicemia Vaccines Product Portfolio Table 97. LABIOFAM Recent Development Table 98. Intervac (PVT) Ltd Company Information Table 99. Intervac (PVT) Ltd Business Overview Table 100. Intervac (PVT) Ltd Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 101. Intervac (PVT) Ltd Hemorrhagic Septicemia Vaccines Product Portfolio Table 102. Intervac (PVT) Ltd Recent Development Table 103. Institute of Veterinary Preventive Medicine Company Information Table 104. Institute of Veterinary Preventive Medicine Business Overview Table 105. Institute of Veterinary Preventive Medicine Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 106. Institute of Veterinary Preventive Medicine Hemorrhagic Septicemia Vaccines Product Portfolio Table 107. Institute of Veterinary Preventive Medicine Recent Development Table 108. Institute of Animal Health and Veterinary Biologicals Company Information Table 109. Institute of Animal Health and Veterinary Biologicals Business Overview Table 110. Institute of Animal Health and Veterinary Biologicals Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 111. Institute of Animal Health and Veterinary Biologicals Hemorrhagic Septicemia Vaccines Product Portfolio Table 112. Institute of Animal Health and Veterinary Biologicals Recent Development Table 113. Indian Immunologicals Limited Company Information Table 114. Indian Immunologicals Limited Business Overview Table 115. Indian Immunologicals Limited Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 116. Indian Immunologicals Limited Hemorrhagic Septicemia Vaccines Product Portfolio Table 117. Indian Immunologicals Limited Recent Development Table 118. FATRO Company Information Table 119. FATRO Business Overview Table 120. FATRO Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 121. FATRO Hemorrhagic Septicemia Vaccines Product Portfolio Table 122. FATRO Recent Development Table 123. Ceva Santé Animale Company Information Table 124. Ceva Santé Animale Business Overview Table 125. Ceva Santé Animale Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 126. Ceva Santé Animale Hemorrhagic Septicemia Vaccines Product Portfolio Table 127. Ceva Santé Animale Recent Development Table 128. C.A. Laboratorios Asociados (CALA) Company Information Table 129. C.A. Laboratorios Asociados (CALA) Business Overview Table 130. C.A. Laboratorios Asociados (CALA) Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 131. C.A. Laboratorios Asociados (CALA) Hemorrhagic Septicemia Vaccines Product Portfolio Table 132. C.A. Laboratorios Asociados (CALA) Recent Development Table 133. Brilliant Bio Pharma Company Information Table 134. Brilliant Bio Pharma Business Overview Table 135. Brilliant Bio Pharma Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 136. Brilliant Bio Pharma Hemorrhagic Septicemia Vaccines Product Portfolio Table 137. Brilliant Bio Pharma Recent Development Table 138. Bio-Labs (PVT) Limited Company Information Table 139. Bio-Labs (PVT) Limited Business Overview Table 140. Bio-Labs (PVT) Limited Hemorrhagic Septicemia Vaccines Sales (m units), Value (US$ Million), Price (US$/k unit) and Gross Margin (2021-2026) Table 141. Bio-Labs (PVT) Limited Hemorrhagic Septicemia Vaccines Product Portfolio Table 142. Bio-Labs (PVT) Limited Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Hemorrhagic Septicemia Vaccines Distributors List Table 146. Hemorrhagic Septicemia Vaccines Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Hemorrhagic Septicemia Vaccines Product Image Figure 2. Global Hemorrhagic Septicemia Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemorrhagic Septicemia Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hemorrhagic Septicemia Vaccines Sales (2021-2032) & (m units) Figure 5. Global Hemorrhagic Septicemia Vaccines Sales Average Price (US$/k unit) & (2021-2032) Figure 6. Global Hemorrhagic Septicemia Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oil–adjuvant Vaccines Image Figure 10. Aluminum hydroxide-adjuvant Vaccines Image Figure 11. Global Hemorrhagic Septicemia Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (m units) Figure 12. Global Hemorrhagic Septicemia Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Hemorrhagic Septicemia Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Hemorrhagic Septicemia Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hemorrhagic Septicemia Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hemorrhagic Septicemia Vaccines Sales Value Share by Type (2021-2032) Figure 17. Cattle Image Figure 18. Buffaloes Image Figure 19. Global Hemorrhagic Septicemia Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (m units) Figure 20. Global Hemorrhagic Septicemia Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Hemorrhagic Septicemia Vaccines Sales Volume Share by Application (2021-2032) Figure 22. Global Hemorrhagic Septicemia Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Hemorrhagic Septicemia Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Hemorrhagic Septicemia Vaccines Sales Value Share by Application (2021-2032) Figure 25. Global Hemorrhagic Septicemia Vaccines Sales by Region: 2021 VS 2025 VS 2032 (m units) Figure 26. Global Hemorrhagic Septicemia Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Hemorrhagic Septicemia Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Hemorrhagic Septicemia Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Hemorrhagic Septicemia Vaccines Sales Value (2021-2032) & (US$ Million) Figure 30. North America Hemorrhagic Septicemia Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Hemorrhagic Septicemia Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Hemorrhagic Septicemia Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Hemorrhagic Septicemia Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Hemorrhagic Septicemia Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Hemorrhagic Septicemia Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. South America Hemorrhagic Septicemia Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Hemorrhagic Septicemia Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Hemorrhagic Septicemia Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Hemorrhagic Septicemia Vaccines Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Hemorrhagic Septicemia Vaccines Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Oil–adjuvant Vaccines
  • Aluminum hydroxide-adjuvant Vaccines
Applications
  • Cattle
  • Buffaloes
Companies covered
  • Zoetis
  • Vecol
  • National Veterinary Research Institute
  • Limor de Colombia
  • Laboratorios Ovejero
  • Laboratorios Laverlam
  • LABIOFAM
  • Intervac (PVT) Ltd
  • Institute of Veterinary Preventive Medicine
  • Institute of Animal Health and Veterinary Biologicals
  • Indian Immunologicals Limited
  • FATRO
  • Ceva Santé Animale
  • C.A. Laboratorios Asociados (CALA)
  • Brilliant Bio Pharma
  • Bio-Labs (PVT) Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hemorrhagic Septicemia Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Hemorrhagic Septicemia Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Hemorrhagic Septicemia Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hemorrhagic Septicemia Vaccines Market Dynamics
  1. 2.1 Hemorrhagic Septicemia Vaccines Industry Trends
  2. 2.2 Hemorrhagic Septicemia Vaccines Industry Drivers
  3. 2.3 Hemorrhagic Septicemia Vaccines Industry Opportunities and Challenges
  4. 2.4 Hemorrhagic Septicemia Vaccines Industry Restraints
3 Hemorrhagic Septicemia Vaccines Market by Company
  1. 3.1 Global Hemorrhagic Septicemia Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Hemorrhagic Septicemia Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Hemorrhagic Septicemia Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Hemorrhagic Septicemia Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Hemorrhagic Septicemia Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Hemorrhagic Septicemia Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Hemorrhagic Septicemia Vaccines Company Product Type and Application
  8. 3.8 Global Hemorrhagic Septicemia Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hemorrhagic Septicemia Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hemorrhagic Septicemia Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hemorrhagic Septicemia Vaccines Market by Type
  1. 4.1 Hemorrhagic Septicemia Vaccines Type Introduction
  2. 4.1.1 Oil–adjuvant Vaccines
  3. 4.1.2 Aluminum hydroxide-adjuvant Vaccines
  4. 4.2 Global Hemorrhagic Septicemia Vaccines Sales Volume by Type
  5. 4.2.1 Global Hemorrhagic Septicemia Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hemorrhagic Septicemia Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Hemorrhagic Septicemia Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Hemorrhagic Septicemia Vaccines Sales Value by Type
  9. 4.3.1 Global Hemorrhagic Septicemia Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hemorrhagic Septicemia Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Hemorrhagic Septicemia Vaccines Sales Value Share by Type (2021-2032)
5 Hemorrhagic Septicemia Vaccines Market by Application
  1. 5.1 Hemorrhagic Septicemia Vaccines Application Introduction
  2. 5.1.1 Cattle
  3. 5.1.2 Buffaloes
  4. 5.2 Global Hemorrhagic Septicemia Vaccines Sales Volume by Application
  5. 5.2.1 Global Hemorrhagic Septicemia Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Hemorrhagic Septicemia Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Hemorrhagic Septicemia Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Hemorrhagic Septicemia Vaccines Sales Value by Application
  9. 5.3.1 Global Hemorrhagic Septicemia Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Hemorrhagic Septicemia Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global Hemorrhagic Septicemia Vaccines Sales Value Share by Application (2021-2032)
6 Hemorrhagic Septicemia Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Hemorrhagic Septicemia Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hemorrhagic Septicemia Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Hemorrhagic Septicemia Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Hemorrhagic Septicemia Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Hemorrhagic Septicemia Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hemorrhagic Septicemia Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hemorrhagic Septicemia Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hemorrhagic Septicemia Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Hemorrhagic Septicemia Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hemorrhagic Septicemia Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Hemorrhagic Septicemia Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hemorrhagic Septicemia Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Hemorrhagic Septicemia Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hemorrhagic Septicemia Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hemorrhagic Septicemia Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hemorrhagic Septicemia Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Hemorrhagic Septicemia Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hemorrhagic Septicemia Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hemorrhagic Septicemia Vaccines Sales Value Share by Country, 2025 VS 2032
7 Hemorrhagic Septicemia Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Hemorrhagic Septicemia Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hemorrhagic Septicemia Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hemorrhagic Septicemia Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Hemorrhagic Septicemia Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Hemorrhagic Septicemia Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Hemorrhagic Septicemia Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hemorrhagic Septicemia Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hemorrhagic Septicemia Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hemorrhagic Septicemia Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hemorrhagic Septicemia Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hemorrhagic Septicemia Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zoetis
  2. 8.1.1 Zoetis Company Information
  3. 8.1.2 Zoetis Business Overview
  4. 8.1.3 Zoetis Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zoetis Hemorrhagic Septicemia Vaccines Product Portfolio
  6. 8.1.5 Zoetis Recent Developments
  7. 8.2 Vecol
  8. 8.2.1 Vecol Company Information
  9. 8.2.2 Vecol Business Overview
  10. 8.2.3 Vecol Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Vecol Hemorrhagic Septicemia Vaccines Product Portfolio
  12. 8.2.5 Vecol Recent Developments
  13. 8.3 National Veterinary Research Institute
  14. 8.3.1 National Veterinary Research Institute Company Information
  15. 8.3.2 National Veterinary Research Institute Business Overview
  16. 8.3.3 National Veterinary Research Institute Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 National Veterinary Research Institute Hemorrhagic Septicemia Vaccines Product Portfolio
  18. 8.3.5 National Veterinary Research Institute Recent Developments
  19. 8.4 Limor de Colombia
  20. 8.4.1 Limor de Colombia Company Information
  21. 8.4.2 Limor de Colombia Business Overview
  22. 8.4.3 Limor de Colombia Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Limor de Colombia Hemorrhagic Septicemia Vaccines Product Portfolio
  24. 8.4.5 Limor de Colombia Recent Developments
  25. 8.5 Laboratorios Ovejero
  26. 8.5.1 Laboratorios Ovejero Company Information
  27. 8.5.2 Laboratorios Ovejero Business Overview
  28. 8.5.3 Laboratorios Ovejero Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Laboratorios Ovejero Hemorrhagic Septicemia Vaccines Product Portfolio
  30. 8.5.5 Laboratorios Ovejero Recent Developments
  31. 8.6 Laboratorios Laverlam
  32. 8.6.1 Laboratorios Laverlam Company Information
  33. 8.6.2 Laboratorios Laverlam Business Overview
  34. 8.6.3 Laboratorios Laverlam Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Laboratorios Laverlam Hemorrhagic Septicemia Vaccines Product Portfolio
  36. 8.6.5 Laboratorios Laverlam Recent Developments
  37. 8.7 LABIOFAM
  38. 8.7.1 LABIOFAM Company Information
  39. 8.7.2 LABIOFAM Business Overview
  40. 8.7.3 LABIOFAM Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 LABIOFAM Hemorrhagic Septicemia Vaccines Product Portfolio
  42. 8.7.5 LABIOFAM Recent Developments
  43. 8.8 Intervac (PVT) Ltd
  44. 8.8.1 Intervac (PVT) Ltd Company Information
  45. 8.8.2 Intervac (PVT) Ltd Business Overview
  46. 8.8.3 Intervac (PVT) Ltd Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Intervac (PVT) Ltd Hemorrhagic Septicemia Vaccines Product Portfolio
  48. 8.8.5 Intervac (PVT) Ltd Recent Developments
  49. 8.9 Institute of Veterinary Preventive Medicine
  50. 8.9.1 Institute of Veterinary Preventive Medicine Company Information
  51. 8.9.2 Institute of Veterinary Preventive Medicine Business Overview
  52. 8.9.3 Institute of Veterinary Preventive Medicine Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Institute of Veterinary Preventive Medicine Hemorrhagic Septicemia Vaccines Product Portfolio
  54. 8.9.5 Institute of Veterinary Preventive Medicine Recent Developments
  55. 8.10 Institute of Animal Health and Veterinary Biologicals
  56. 8.10.1 Institute of Animal Health and Veterinary Biologicals Company Information
  57. 8.10.2 Institute of Animal Health and Veterinary Biologicals Business Overview
  58. 8.10.3 Institute of Animal Health and Veterinary Biologicals Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Institute of Animal Health and Veterinary Biologicals Hemorrhagic Septicemia Vaccines Product Portfolio
  60. 8.10.5 Institute of Animal Health and Veterinary Biologicals Recent Developments
  61. 8.11 Indian Immunologicals Limited
  62. 8.11.1 Indian Immunologicals Limited Company Information
  63. 8.11.2 Indian Immunologicals Limited Business Overview
  64. 8.11.3 Indian Immunologicals Limited Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Indian Immunologicals Limited Hemorrhagic Septicemia Vaccines Product Portfolio
  66. 8.11.5 Indian Immunologicals Limited Recent Developments
  67. 8.12 FATRO
  68. 8.12.1 FATRO Company Information
  69. 8.12.2 FATRO Business Overview
  70. 8.12.3 FATRO Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 FATRO Hemorrhagic Septicemia Vaccines Product Portfolio
  72. 8.12.5 FATRO Recent Developments
  73. 8.13 Ceva Santé Animale
  74. 8.13.1 Ceva Santé Animale Company Information
  75. 8.13.2 Ceva Santé Animale Business Overview
  76. 8.13.3 Ceva Santé Animale Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Ceva Santé Animale Hemorrhagic Septicemia Vaccines Product Portfolio
  78. 8.13.5 Ceva Santé Animale Recent Developments
  79. 8.14 C.A. Laboratorios Asociados (CALA)
  80. 8.14.1 C.A. Laboratorios Asociados (CALA) Company Information
  81. 8.14.2 C.A. Laboratorios Asociados (CALA) Business Overview
  82. 8.14.3 C.A. Laboratorios Asociados (CALA) Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 C.A. Laboratorios Asociados (CALA) Hemorrhagic Septicemia Vaccines Product Portfolio
  84. 8.14.5 C.A. Laboratorios Asociados (CALA) Recent Developments
  85. 8.15 Brilliant Bio Pharma
  86. 8.15.1 Brilliant Bio Pharma Company Information
  87. 8.15.2 Brilliant Bio Pharma Business Overview
  88. 8.15.3 Brilliant Bio Pharma Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Brilliant Bio Pharma Hemorrhagic Septicemia Vaccines Product Portfolio
  90. 8.15.5 Brilliant Bio Pharma Recent Developments
  91. 8.16 Bio-Labs (PVT) Limited
  92. 8.16.1 Bio-Labs (PVT) Limited Company Information
  93. 8.16.2 Bio-Labs (PVT) Limited Business Overview
  94. 8.16.3 Bio-Labs (PVT) Limited Hemorrhagic Septicemia Vaccines Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Bio-Labs (PVT) Limited Hemorrhagic Septicemia Vaccines Product Portfolio
  96. 8.16.5 Bio-Labs (PVT) Limited Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hemorrhagic Septicemia Vaccines Value Chain Analysis
  2. 9.1.1 Hemorrhagic Septicemia Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hemorrhagic Septicemia Vaccines Sales Mode & Process
  6. 9.2 Hemorrhagic Septicemia Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hemorrhagic Septicemia Vaccines Distributors
  9. 9.2.3 Hemorrhagic Septicemia Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst